|
Semaglutide’s Heart Benefits Extend Beyond Weight Loss
|
Written by: J. Smith |
Hits: 168
|
|
Terns Ends Development of Oral Obesity Drug After Phase 2 Results
|
Written by: J. Smith |
Hits: 313
|
|
FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
|
Written by: J. Smith |
Hits: 254
|
|
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
|
Written by: J. Smith |
Hits: 150
|
|
Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
|
Written by: J. Smith |
Hits: 580
|
|
Dexcom Introduces Smart Basal at EASD 2025
|
Written by: J. Smith |
Hits: 500
|
|
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
|
Written by: J. Smith |
Hits: 194
|
|
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
|
Written by: J. Smith |
Hits: 279
|
|
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration
|
Written by: J. Smith |
Hits: 249
|
|
CVS Caremark Faces Lawsuit Over Dropping Zepbound
|
Written by: J. Smith |
Hits: 210
|
